首页 > 最新文献

International Journal of Breast Cancer最新文献

英文 中文
Breast Cancer Screening Using a Modified Inertial Projective Algorithms for Split Feasibility Problems. 使用改进的惯性投影算法进行乳腺癌筛查的分割可行性问题。
IF 1.9 Q3 Medicine Pub Date : 2023-01-01 DOI: 10.1155/2023/2060375
Pennipat Nabheerong, Warissara Kiththiworaphongkich, Watcharaporn Cholamjiak

To detect breast cancer in mammography screening practice, we modify the inertial relaxed CQ algorithm with Mann's iteration for solving split feasibility problems in real Hilbert spaces to apply in an extreme learning machine as an optimizer. Weak convergence of the proposed algorithm is proved under certain mild conditions. Moreover, we present the advantage of our algorithm by comparing it with existing machine learning methods. The highest performance value of 85.03% accuracy, 82.56% precision, 87.65% recall, and 85.03% F1-score show that our algorithm performs better than the other machine learning models.

为了在乳腺x线摄影筛查实践中检测乳腺癌,我们改进了Mann迭代求解实际Hilbert空间中分裂可行性问题的惯性松弛CQ算法,将其作为优化器应用于极限学习机。在一定的温和条件下证明了该算法的弱收敛性。此外,通过与现有机器学习方法的比较,我们展示了我们算法的优势。85.03%的准确率、82.56%的精度、87.65%的召回率和85.03%的f1分数的最高性能值表明,我们的算法比其他机器学习模型性能更好。
{"title":"Breast Cancer Screening Using a Modified Inertial Projective Algorithms for Split Feasibility Problems.","authors":"Pennipat Nabheerong,&nbsp;Warissara Kiththiworaphongkich,&nbsp;Watcharaporn Cholamjiak","doi":"10.1155/2023/2060375","DOIUrl":"https://doi.org/10.1155/2023/2060375","url":null,"abstract":"<p><p>To detect breast cancer in mammography screening practice, we modify the inertial relaxed CQ algorithm with Mann's iteration for solving split feasibility problems in real Hilbert spaces to apply in an extreme learning machine as an optimizer. Weak convergence of the proposed algorithm is proved under certain mild conditions. Moreover, we present the advantage of our algorithm by comparing it with existing machine learning methods. The highest performance value of 85.03% accuracy, 82.56% precision, 87.65% recall, and 85.03% F1-score show that our algorithm performs better than the other machine learning models.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501843/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10360927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Latent Toxoplasmosis among Breast Cancer Patients in Jahrom, South of Iran. 伊朗南部贾罗姆市乳腺癌患者中的潜伏弓形虫病
IF 1.9 Q3 Medicine Pub Date : 2023-01-01 DOI: 10.1155/2023/4792260
Marzeieh Haghbin, Salar Maani, Mohammad Aref Bagherzadeh, Ahmadreza Bazmjoo, Heshmatollah Shakeri, Ali Taghipour, Shahab Falahi, Azra Kenarkoohi, Milad Badri, Amir Abdoli

Objective: Reactivation of latent toxoplasmosis is the main cause of severe infection among immunocompromised patients, including patients with cancer. Hence, this study is aimed at screening the status of Toxoplasma gondii infection among breast cancer patients by serological and molecular methods and determining their associated risk factors in Jahrom County, Fars Province, south of Iran.

Methods: One hundred and seven women with breast cancer (aged 34 to 80 years) were screened for anti-T. gondii antibodies (IgG and IgM) during 2019-2020. A questionnaire regarding demographic factors was filled out by participants. Molecular detection was performed by polymerase chain reaction (PCR) using the primer pair targeting the repetitive element (RE) gene of T. gondii. The risk factors and demographic data were analyzed by SPSS software (ver. 20, Chicago, IL, USA) using the Chi-squared test.

Results: Anti-T. gondii IgG was detected in 45.8% (49/107) of the patients, which indicates latent infection, but anti-T. gondii IgM and PCR were negative in all samples. Demographic factors revealed a statistically significant increased T. gondii seropositivity among nonmenopause cancer patients (P < 0.0005), patients without previous breast cancer (P = 0.0001), and human epidermal growth factor receptor 2- (HER2-) negative patients (P = 0.00002). As such, patients with a history of previous abortions and who were at stages II, III, and IIII of cancer had higher seropositivity rates than patients without a history of previous abortions or who were at stage I cancer, but the statistical analysis was not significant. We did not find a statistically significant association between T. gondii seropositivity and other risk factors of toxoplasmosis (e.g., education level, type of water source, washing raw fruits and vegetables, consumption of raw or undercooked meat, and contact with soil, cats, and domestic animal).

Conclusion: A high seroprevalence rate of latent T. gondii infection was detected among patients with breast cancer; hence, these patients may be at high risk for reactivation of latent infection. Screening of T. gondii infection is recommended to detect active infection among patients with malignancies.

目的:潜伏性弓形虫病的再激活是免疫功能低下患者(包括癌症患者)严重感染的主要原因。因此,本研究旨在通过血清学和分子方法筛查伊朗南部法尔斯省Jahrom县乳腺癌患者中刚地弓形虫感染状况,并确定其相关危险因素。方法:对117例乳腺癌患者(34 ~ 80岁)进行抗t抗体筛查。2019-2020年弓形虫抗体(IgG和IgM)。参与者填写了一份关于人口因素的调查问卷。采用聚合酶链式反应(PCR)对刚地弓形虫重复元件(RE)基因进行分子检测。危险因素及人口学资料采用SPSS软件进行分析。20,芝加哥,伊利诺伊州,美国),使用卡方检验。结果:Anti-T。45.8%(49/107)的患者检出弓形虫IgG,提示潜伏性感染;所有样本的IgM和PCR检测均为阴性。人口统计学因素显示,在非绝经期癌症患者(P < 0.0005)、既往无乳腺癌患者(P = 0.0001)和人表皮生长因子受体2- (HER2-)阴性患者(P = 0.00002)中,弓形虫血清阳性升高具有统计学意义。因此,有流产史和II期、III期、III期癌症患者血清阳性率高于无流产史和I期癌症患者,但统计学分析无显著性差异。我们没有发现弓形虫血清阳性与弓形虫病的其他危险因素(如教育水平、水源类型、清洗生水果和蔬菜、食用生的或未煮熟的肉类、接触土壤、猫和家畜)之间存在统计学上显著的关联。结论:乳腺癌患者血清潜伏性弓形虫感染率较高;因此,这些患者可能处于潜伏感染再激活的高风险中。建议筛查弓形虫感染,以发现恶性肿瘤患者的活动性感染。
{"title":"Latent Toxoplasmosis among Breast Cancer Patients in Jahrom, South of Iran.","authors":"Marzeieh Haghbin,&nbsp;Salar Maani,&nbsp;Mohammad Aref Bagherzadeh,&nbsp;Ahmadreza Bazmjoo,&nbsp;Heshmatollah Shakeri,&nbsp;Ali Taghipour,&nbsp;Shahab Falahi,&nbsp;Azra Kenarkoohi,&nbsp;Milad Badri,&nbsp;Amir Abdoli","doi":"10.1155/2023/4792260","DOIUrl":"https://doi.org/10.1155/2023/4792260","url":null,"abstract":"<p><strong>Objective: </strong>Reactivation of latent toxoplasmosis is the main cause of severe infection among immunocompromised patients, including patients with cancer. Hence, this study is aimed at screening the status of <i>Toxoplasma gondii</i> infection among breast cancer patients by serological and molecular methods and determining their associated risk factors in Jahrom County, Fars Province, south of Iran.</p><p><strong>Methods: </strong>One hundred and seven women with breast cancer (aged 34 to 80 years) were screened for anti-<i>T. gondii</i> antibodies (IgG and IgM) during 2019-2020. A questionnaire regarding demographic factors was filled out by participants. Molecular detection was performed by polymerase chain reaction (PCR) using the primer pair targeting the repetitive element (RE) gene of <i>T. gondii</i>. The risk factors and demographic data were analyzed by SPSS software (ver. 20, Chicago, IL, USA) using the Chi-squared test.</p><p><strong>Results: </strong>Anti-<i>T. gondii</i> IgG was detected in 45.8% (49/107) of the patients, which indicates latent infection, but anti-<i>T. gondii</i> IgM and PCR were negative in all samples. Demographic factors revealed a statistically significant increased <i>T. gondii</i> seropositivity among nonmenopause cancer patients (<i>P</i> < 0.0005), patients without previous breast cancer (<i>P</i> = 0.0001), and human epidermal growth factor receptor 2- (<i>HER2-</i>) negative patients (<i>P</i> = 0.00002). As such, patients with a history of previous abortions and who were at stages II, III, and IIII of cancer had higher seropositivity rates than patients without a history of previous abortions or who were at stage I cancer, but the statistical analysis was not significant. We did not find a statistically significant association between <i>T. gondii</i> seropositivity and other risk factors of toxoplasmosis (e.g., education level, type of water source, washing raw fruits and vegetables, consumption of raw or undercooked meat, and contact with soil, cats, and domestic animal).</p><p><strong>Conclusion: </strong>A high seroprevalence rate of latent <i>T. gondii</i> infection was detected among patients with breast cancer; hence, these patients may be at high risk for reactivation of latent infection. Screening of <i>T. gondii</i> infection is recommended to detect active infection among patients with malignancies.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386900/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9899701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deep Inferior Epigastric Perforator Flap for Immediate Breast Reconstruction following Mastectomy in Breast Cancer Patients: An Initial Experience in Vietnam. 上腹部深下穿支皮瓣用于乳腺癌患者乳房切除术后立即乳房重建:越南的初步经验。
IF 1.9 Q3 Medicine Pub Date : 2023-01-01 DOI: 10.1155/2023/5964040
Xuan Hau Nguyen, Viet Dung Pham Thi, Xuan Hien Nguyen, Thi Dung Vu, Hop Nhan Nguyen, Quang Dao Pham, Van Ty Ngo

Background: Breast reconstruction in breast cancer patients is an optional surgery that improves the quality of life while preserving the efficacy of chemotherapy and radiotherapy. Deep inferior epigastric perforator (DIEP) flap is a new but reliable and safe technique for autologous breast reconstruction. After mastectomy, immediate reconstruction is the preferred method because of its aesthetic result and convenience. This study is aimed at summarizing our experience in DIEP flap for immediate breast reconstruction.

Methods: A prospective study was performed on 30 breast cancer patients who underwent intermediate breast reconstruction for DIEP flap after mastectomy from June 2019 to June 2021 in Hanoi Medical University Hospital. Clinicopathology characteristics, tumor stage, treatment, and complications were evaluated.

Result: The mean age of patients was 44.9 (range: 29-73 years). 86.7% of patients were in stages I and II. Five patients (16.7%) received neoadjuvant chemotherapy. 20 patients (66.7%) underwent nipple-sparing mastectomy (NSM) procedures. The mean operating time was 341 minutes. The mean time to receive chemotherapy was 34.68 days. The mean number of perforators was 1.30. The overall flap success rate was 90%. Twelve patients (40%) experienced complications. Four patients (13.3%) returned to the operating room due to venous congestions. Two patients (6.67%) had complete flap loss. Other complication: fat necrosis (6.7%), seroma (13.3%), partial flap loss (3.3%), abdominal wound dehiscence (6.7%), pneumonia (3.3%), and pulmonary embolism (6.7%). After one-month postoperation, 88.9% of patients were satisfied with their breasts, and 74.07% were satisfied with the operation.

Conclusion: DIEP flap is a new but reliable and safe technique for autologous breast reconstruction. Though patients opting for breast reconstruction still have a low risk of complication and reconstruction failure, this procedure should be used more frequently in appropriate patients to improve their quality of life.

背景:乳腺癌患者的乳房重建术是一种可选择的手术,可在保留化疗和放疗疗效的同时提高患者的生活质量。深下腹穿支皮瓣是一种安全可靠的自体乳房重建新技术。乳房切除术后,立即重建因其美观和方便而成为首选方法。本研究旨在总结DIEP皮瓣用于乳房即刻再造术的经验。方法:对2019年6月至2021年6月在河内医科大学医院行乳腺切除术后DIEP皮瓣中期乳房重建的30例乳腺癌患者进行前瞻性研究。评估临床病理特征、肿瘤分期、治疗方法及并发症。结果:患者平均年龄44.9岁(29 ~ 73岁)。86.7%的患者处于I期和II期。5例(16.7%)患者接受了新辅助化疗。20例(66.7%)患者行保留乳头乳房切除术(NSM)。平均手术时间为341分钟。平均化疗时间为34.68天。平均穿孔数为1.30个。皮瓣总成功率为90%。12例(40%)出现并发症。4例(13.3%)因静脉充血返回手术室。2例(6.67%)皮瓣完全丢失。其他并发症:脂肪坏死(6.7%)、血清肿(13.3%)、部分皮瓣缺失(3.3%)、腹部伤口裂开(6.7%)、肺炎(3.3%)、肺栓塞(6.7%)。术后1个月,88.9%的患者对乳房满意,74.07%的患者对手术满意。结论:DIEP皮瓣是一种安全可靠的自体乳房重建新技术。虽然选择乳房再造术的患者并发症和再造术失败的风险仍然很低,但在适当的患者中应该更频繁地使用这一手术,以提高他们的生活质量。
{"title":"Deep Inferior Epigastric Perforator Flap for Immediate Breast Reconstruction following Mastectomy in Breast Cancer Patients: An Initial Experience in Vietnam.","authors":"Xuan Hau Nguyen,&nbsp;Viet Dung Pham Thi,&nbsp;Xuan Hien Nguyen,&nbsp;Thi Dung Vu,&nbsp;Hop Nhan Nguyen,&nbsp;Quang Dao Pham,&nbsp;Van Ty Ngo","doi":"10.1155/2023/5964040","DOIUrl":"https://doi.org/10.1155/2023/5964040","url":null,"abstract":"<p><strong>Background: </strong>Breast reconstruction in breast cancer patients is an optional surgery that improves the quality of life while preserving the efficacy of chemotherapy and radiotherapy. Deep inferior epigastric perforator (DIEP) flap is a new but reliable and safe technique for autologous breast reconstruction. After mastectomy, immediate reconstruction is the preferred method because of its aesthetic result and convenience. This study is aimed at summarizing our experience in DIEP flap for immediate breast reconstruction.</p><p><strong>Methods: </strong>A prospective study was performed on 30 breast cancer patients who underwent intermediate breast reconstruction for DIEP flap after mastectomy from June 2019 to June 2021 in Hanoi Medical University Hospital. Clinicopathology characteristics, tumor stage, treatment, and complications were evaluated.</p><p><strong>Result: </strong>The mean age of patients was 44.9 (range: 29-73 years). 86.7% of patients were in stages I and II. Five patients (16.7%) received neoadjuvant chemotherapy. 20 patients (66.7%) underwent nipple-sparing mastectomy (NSM) procedures. The mean operating time was 341 minutes. The mean time to receive chemotherapy was 34.68 days. The mean number of perforators was 1.30. The overall flap success rate was 90%. Twelve patients (40%) experienced complications. Four patients (13.3%) returned to the operating room due to venous congestions. Two patients (6.67%) had complete flap loss. Other complication: fat necrosis (6.7%), seroma (13.3%), partial flap loss (3.3%), abdominal wound dehiscence (6.7%), pneumonia (3.3%), and pulmonary embolism (6.7%). After one-month postoperation, 88.9% of patients were satisfied with their breasts, and 74.07% were satisfied with the operation.</p><p><strong>Conclusion: </strong>DIEP flap is a new but reliable and safe technique for autologous breast reconstruction. Though patients opting for breast reconstruction still have a low risk of complication and reconstruction failure, this procedure should be used more frequently in appropriate patients to improve their quality of life.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845050/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10554208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Galangin-Loaded Gold Nanoparticles: Molecular Mechanisms of Antiangiogenesis Properties in Breast Cancer. 含高良姜的金纳米颗粒:乳腺癌中抗血管生成特性的分子机制。
IF 1.9 Q3 Medicine Pub Date : 2023-01-01 DOI: 10.1155/2023/3251211
Malik H Qaddoori, Hanady S Al-Shmgani

Angiogenesis is important for tissue during normal physiological processes as well as in a number of diseases, including cancer. Drug resistance is one of the largest difficulties to antiangiogenesis therapy. Due to their lower cytotoxicity and stronger pharmacological advantage, phytochemical anticancer medications have a number of advantages over chemical chemotherapeutic drugs. In the current study, the effectiveness of AuNPs, AuNPs-GAL, and free galangin as an antiangiogenesis agent was evaluated. Different physicochemical and molecular approaches have been used including the characterization, cytotoxicity, scratch wound healing assay, and gene expression of VEGF and ERKI in MCF-7 and MDA-MB-231 human breast cancer cell line. Results obtained from MTT assay show cell growth reduction in a time- and dose-dependent aspect; also, in comparison to individual treatment, a synergistic impact was indicated. CAM assay results demonstrated galangin-gold nanoparticle capacity to suppress angiogenesis in chick embryo. Additionally, altering VEGF and ERKI gene expression was recorded. Taken together, all the results can conclude that galangin-conjugated gold nanoparticles can be a promising antiangiogenesis supplemental drug in breast cancer treatment.

血管生成在正常生理过程中对组织以及包括癌症在内的许多疾病中都很重要。耐药是抗血管生成治疗的最大困难之一。由于植物化学抗癌药物具有较低的细胞毒性和较强的药理优势,因此与化学化疗药物相比具有许多优势。在本研究中,评估了AuNPs、AuNPs- gal和游离高良姜素作为抗血管生成剂的有效性。在MCF-7和MDA-MB-231人乳腺癌细胞系中,使用了不同的物理化学和分子方法,包括表征、细胞毒性、划伤愈合试验和VEGF和ERKI的基因表达。MTT试验结果显示细胞生长呈时间和剂量依赖性;此外,与单独治疗相比,还显示了协同效应。CAM实验结果表明高良姜金纳米颗粒能够抑制鸡胚血管生成。此外,记录VEGF和ERKI基因表达的变化。综上所述,高良姜素结合的金纳米颗粒可能是一种很有前途的抗血管生成补充药物,用于乳腺癌治疗。
{"title":"Galangin-Loaded Gold Nanoparticles: Molecular Mechanisms of Antiangiogenesis Properties in Breast Cancer.","authors":"Malik H Qaddoori,&nbsp;Hanady S Al-Shmgani","doi":"10.1155/2023/3251211","DOIUrl":"https://doi.org/10.1155/2023/3251211","url":null,"abstract":"<p><p>Angiogenesis is important for tissue during normal physiological processes as well as in a number of diseases, including cancer. Drug resistance is one of the largest difficulties to antiangiogenesis therapy. Due to their lower cytotoxicity and stronger pharmacological advantage, phytochemical anticancer medications have a number of advantages over chemical chemotherapeutic drugs. In the current study, the effectiveness of AuNPs, AuNPs-GAL, and free galangin as an antiangiogenesis agent was evaluated. Different physicochemical and molecular approaches have been used including the characterization, cytotoxicity, scratch wound healing assay, and gene expression of <i>VEGF</i> and <i>ERKI</i> in MCF-7 and MDA-MB-231 human breast cancer cell line. Results obtained from MTT assay show cell growth reduction in a time- and dose-dependent aspect; also, in comparison to individual treatment, a synergistic impact was indicated. CAM assay results demonstrated galangin-gold nanoparticle capacity to suppress angiogenesis in chick embryo. Additionally, altering <i>VEGF</i> and <i>ERKI</i> gene expression was recorded. Taken together, all the results can conclude that galangin-conjugated gold nanoparticles can be a promising antiangiogenesis supplemental drug in breast cancer treatment.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950320/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10789219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Papillary Carcinoma of Breast: Clinicopathological Characteristics, Management, and Survival. 乳腺乳头状癌:临床病理特征,管理和生存。
IF 1.9 Q3 Medicine Pub Date : 2022-10-13 eCollection Date: 2022-01-01 DOI: 10.1155/2022/5427837
Bushra Rehman, Anam Mumtaz, Barka Sajjad, Namra Urooj, Sameen Mohtasham Khan, M Toqeer Zahid, Huma Mannan, M Zulqarnain Chaudhary, Amina Khan, M Asad Parvaiz

Objective: To study clinicopathological features, treatment strategies, and prognosis of papillary carcinoma of breast. Material and Methods. Data from 58 patients were retrospectively reviewed from January 2010 to December 2016. Four types of papillary carcinoma (on final resected specimen) were included, i.e., invasive papillary carcinoma (IPC), intracystic (encapsulated) papillary carcinoma (EPC), solid papillary carcinoma (SPC), and papillary DCIS (ductal carcinoma in situ). Various features of the four types were observed and compared.

Results: Of the 58 patients, 8 were males (13.7%). The mean age at presentation was 61 years; the mean tumor size was 33 mm. The frequency of each histological type was as follows: IPC (n = 22/38%), EPC (n = 22/38%), SPC (n = 12/20.6%), and papillary DCIS (n = 2/3.4%). Only two patients were ER negative (both IPC). HER-2 Neu was positive in 3 patients only, out of which 2 died of progressive disease (one EPC and one IPC). LN metastasis was present in 3 (5%) patients (one in each of 1st three types) and only one died of bone metastasis that was also Her-2Neu positive. All patients underwent upfront surgery except two patients who had synchronous IDC on the contralateral side. Breast conservation surgery (BCS) was performed in 34 (58.6%) and mastectomy in 22 (37.9%) patients. 13 patients did not undergo invasive axillary staging; the rest of 43 (74%) patients did (32 sentinel biopsy and 11 axillary dissection). Chemotherapy was given to 18 patients (31%), mostly to IPC (n = 12). Only 2 patients had bone metastasis (one was IPC and one EPC). Cancer-related death was observed in 3 patients. For all groups combined, 5-year OS was 98% and DFS was 92%.

Conclusion: Overall, papillary carcinoma of the breast has an excellent prognosis, even though less intense treatment modalities were used. It is still difficult to define the optimum management and avoid overtreatment, given the limited data in the literature.

目的:探讨乳腺乳头状癌的临床病理特点、治疗策略及预后。材料和方法。对2010年1月至2016年12月58例患者的数据进行回顾性分析。包括四种类型的乳头状癌(最终切除标本),即浸润性乳头状癌(IPC),囊内(包封)乳头状癌(EPC),实体性乳头状癌(SPC)和乳头状DCIS(导管原位癌)。观察并比较四种类型的各种特征。结果:58例患者中,男性8例(13.7%)。发病时平均年龄61岁;平均肿瘤大小为33 mm。各组织学类型的发生率分别为:IPC (n = 22/38%)、EPC (n = 22/38%)、SPC (n = 12/20.6%)、乳头状DCIS (n = 2/3.4%)。仅有2例患者ER阴性(均为IPC)。只有3例患者HER-2 Neu阳性,其中2例死于疾病进展(1例EPC和1例IPC)。3例(5%)患者出现淋巴结转移(前三种类型各1例),仅有1例死于Her-2Neu阳性的骨转移。除2例对侧同步IDC患者外,所有患者均行术前手术。保乳手术34例(58.6%),乳房切除术22例(37.9%)。13例未行浸润性腋窝分期;其余43例(74%)患者进行了检查(32例前哨活检和11例腋窝清扫)。化疗18例(31%),主要为IPC (n = 12)。仅有2例发生骨转移(1例IPC, 1例EPC)。3例患者出现肿瘤相关死亡。所有组的5年OS为98%,DFS为92%。结论:总体而言,即使采用较低强度的治疗方式,乳腺乳头状癌的预后也很好。鉴于文献资料有限,确定最佳管理和避免过度治疗仍然很困难。
{"title":"Papillary Carcinoma of Breast: Clinicopathological Characteristics, Management, and Survival.","authors":"Bushra Rehman,&nbsp;Anam Mumtaz,&nbsp;Barka Sajjad,&nbsp;Namra Urooj,&nbsp;Sameen Mohtasham Khan,&nbsp;M Toqeer Zahid,&nbsp;Huma Mannan,&nbsp;M Zulqarnain Chaudhary,&nbsp;Amina Khan,&nbsp;M Asad Parvaiz","doi":"10.1155/2022/5427837","DOIUrl":"https://doi.org/10.1155/2022/5427837","url":null,"abstract":"<p><strong>Objective: </strong>To study clinicopathological features, treatment strategies, and prognosis of papillary carcinoma of breast. <i>Material and Methods.</i> Data from 58 patients were retrospectively reviewed from January 2010 to December 2016. Four types of papillary carcinoma (on final resected specimen) were included, i.e., invasive papillary carcinoma (IPC), intracystic (encapsulated) papillary carcinoma (EPC), solid papillary carcinoma (SPC), and papillary DCIS (ductal carcinoma in situ). Various features of the four types were observed and compared.</p><p><strong>Results: </strong>Of the 58 patients, 8 were males (13.7%). The mean age at presentation was 61 years; the mean tumor size was 33 mm. The frequency of each histological type was as follows: IPC (<i>n</i> = 22/38%), EPC (<i>n</i> = 22/38%), SPC (<i>n</i> = 12/20.6%), and papillary DCIS (<i>n</i> = 2/3.4%). Only two patients were ER negative (both IPC). HER-2 Neu was positive in 3 patients only, out of which 2 died of progressive disease (one EPC and one IPC). LN metastasis was present in 3 (5%) patients (one in each of 1st three types) and only one died of bone metastasis that was also Her-2Neu positive. All patients underwent upfront surgery except two patients who had synchronous IDC on the contralateral side. Breast conservation surgery (BCS) was performed in 34 (58.6%) and mastectomy in 22 (37.9%) patients. 13 patients did not undergo invasive axillary staging; the rest of 43 (74%) patients did (32 sentinel biopsy and 11 axillary dissection). Chemotherapy was given to 18 patients (31%), mostly to IPC (<i>n</i> = 12). Only 2 patients had bone metastasis (one was IPC and one EPC). Cancer-related death was observed in 3 patients. For all groups combined, 5-year OS was 98% and DFS was 92%.</p><p><strong>Conclusion: </strong>Overall, papillary carcinoma of the breast has an excellent prognosis, even though less intense treatment modalities were used. It is still difficult to define the optimum management and avoid overtreatment, given the limited data in the literature.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40566270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Study of Single Nucleotide Polymorphisms Associated with Breast Cancer Patients among Arab Ancestries. 与阿拉伯血统乳腺癌患者相关的单核苷酸多态性研究
IF 1.6 Q4 ONCOLOGY Pub Date : 2022-10-11 eCollection Date: 2022-01-01 DOI: 10.1155/2022/2442109
Yasser Osman, Tarek Elsharkawy, Tariq Mohammad Hashim, Jumana Abdulwahab Alratroot, Fatima Aljindan, Liqa Almulla, Hind Saleh Alsuwat, Waad Mohammed Al Otaibi, Fatma Mohammed Hegazi, Abdallah M Ibrahim, J Francis Borgio, Sayed AbdulAzeez

The aim of this study is to investigate the single nucleotide polymorphisms (SNPs) associated with breast cancer in our population of Arab patients. We investigated 26 breast cancer patients and an equal number of healthy age- and sex-matched control volunteers. We examined the exome wide microarray-based biomarkers and screened 243,345 SNPs for their possible significant association with our breast cancer patients. Successfully, we identified the most significant (p value ≤9.14 × 10-09) four associated SNPs [SNRK and SNRK-AS1-rs202018563G; BRCA2-rs2227943C; ZNF484-rs199826847C; and DCPS-rs1695739G] among persons with breast cancer versus the healthy controls even after Bonferroni corrections (p value <2.05 × 10-07). Although our patients' numbers were limited, the identified SNPs might shed some light on certain breast cancer-associated functional multigenic variations in Arab patients. We assert on the importance of more extensive large-scale analysis to confirm the candidate biomarkers and possible target genes of breast cancer among Arab ancestries.

本研究的目的是调查阿拉伯患者中与乳腺癌相关的单核苷酸多态性(SNPs)。我们调查了 26 名乳腺癌患者和同等数量的年龄和性别匹配的健康对照志愿者。我们检查了基于外显子组宽芯片的生物标记物,并筛选了 243,345 个 SNPs,以确定它们与乳腺癌患者之间可能存在的显著关联。即使经过 Bonferroni 校正(p 值为 -07),我们还是成功地在乳腺癌患者与健康对照中发现了最显著(p 值≤9.14 × 10-09)的四个相关 SNPs [SNRK、SNRK-AS1-rs202018563G;BRCA2-rs2227943C;ZNF484-rs199826847C;DCPS-rs1695739G]。虽然我们的患者人数有限,但所发现的 SNPs 可能会揭示阿拉伯患者中某些与乳腺癌相关的功能性多基因变异。我们认为,必须进行更广泛的大规模分析,以确认阿拉伯血统中乳腺癌的候选生物标志物和可能的靶基因。
{"title":"Study of Single Nucleotide Polymorphisms Associated with Breast Cancer Patients among Arab Ancestries.","authors":"Yasser Osman, Tarek Elsharkawy, Tariq Mohammad Hashim, Jumana Abdulwahab Alratroot, Fatima Aljindan, Liqa Almulla, Hind Saleh Alsuwat, Waad Mohammed Al Otaibi, Fatma Mohammed Hegazi, Abdallah M Ibrahim, J Francis Borgio, Sayed AbdulAzeez","doi":"10.1155/2022/2442109","DOIUrl":"10.1155/2022/2442109","url":null,"abstract":"<p><p>The aim of this study is to investigate the single nucleotide polymorphisms (SNPs) associated with breast cancer in our population of Arab patients. We investigated 26 breast cancer patients and an equal number of healthy age- and sex-matched control volunteers. We examined the exome wide microarray-based biomarkers and screened 243,345 SNPs for their possible significant association with our breast cancer patients. Successfully, we identified the most significant (<i>p</i> value ≤9.14 × 10<sup>-09</sup>) four associated SNPs [<i>SNRK</i> and <i>SNRK-AS1-</i>rs202018563G; <i>BRCA2-</i>rs2227943C; <i>ZNF484-</i>rs199826847C; and <i>DCPS-</i>rs1695739G] among persons with breast cancer versus the healthy controls even after Bonferroni corrections (<i>p</i> value <2.05 × 10<sup>-07</sup>). Although our patients' numbers were limited, the identified SNPs might shed some light on certain breast cancer-associated functional multigenic variations in Arab patients. We assert on the importance of more extensive large-scale analysis to confirm the candidate biomarkers and possible target genes of breast cancer among Arab ancestries.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40650435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between Oxidative Stress Parameters and Hematological Indices in Breast Cancer Patients. 乳腺癌患者氧化应激参数与血液学指标的关系
IF 1.9 Q3 Medicine Pub Date : 2022-10-03 eCollection Date: 2022-01-01 DOI: 10.1155/2022/1459410
Hiva Danesh, Nasrin Ziamajidi, Seyed Alireza Mesbah-Namin, Nahid Nafisi, Roghayeh Abbasalipourkabir

Background: Breast cancer is one of the leading causes of death in women worldwide. This causes an increase in free radicals, resulting in oxidative stress. The aim of this study was to determine the effect of breast cancer on oxidative stress and its relationship with hematological indices.

Methods: This case-control study included 43 women with breast cancer and 37 age-matched healthy controls. Oxidative stress and its correlation with hematological profiles over seven months were evaluated. Finally, the data were compared between the two groups using the t-test and Pearson's test, and the results were analyzed using the SPSS 24 software.

Results: The results revealed that patients with breast cancer had significantly increased hemoglobin (HB), hematocrit (HCT), mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH) levels compared with healthy subjects (p < 0.05). In addition, oxidative stress parameters, such as superoxide dismutase (SOD), catalase (CAT), total oxidant status (TOS), and total antioxidant capacity (TAC), were significantly elevated. Glutathione peroxidase (GPX) and malondialdehyde (MDA) were significantly lower in patients with breast cancer than in the control group (p < 0.05). Statistical significance in hematological indices showed a positive or negative correlation with oxidative stress parameters.

Conclusion: Women with breast cancer showed a deranged complete blood count (CBC) pattern compared to healthy individuals.

背景:乳腺癌是全世界妇女死亡的主要原因之一。这会导致自由基增加,导致氧化应激。本研究的目的是确定乳腺癌对氧化应激的影响及其与血液指标的关系。方法:本病例对照研究包括43名乳腺癌妇女和37名年龄匹配的健康对照。在7个月内评估氧化应激及其与血液学特征的相关性。最后,采用t检验和Pearson检验对两组数据进行比较,并采用SPSS 24软件对结果进行分析。结果:乳腺癌患者血红蛋白(HB)、红细胞压积(HCT)、平均红细胞体积(MCV)、平均红细胞血红蛋白(MCH)水平均显著高于健康人群(p < 0.05)。此外,氧化应激参数,如超氧化物歧化酶(SOD)、过氧化氢酶(CAT)、总氧化状态(TOS)和总抗氧化能力(TAC)显著升高。乳腺癌患者谷胱甘肽过氧化物酶(GPX)、丙二醛(MDA)水平明显低于对照组(p < 0.05)。血液学指标与氧化应激参数呈正相关或负相关,均有统计学意义。结论:与健康个体相比,乳腺癌患者的全血细胞计数(CBC)模式紊乱。
{"title":"Association between Oxidative Stress Parameters and Hematological Indices in Breast Cancer Patients.","authors":"Hiva Danesh,&nbsp;Nasrin Ziamajidi,&nbsp;Seyed Alireza Mesbah-Namin,&nbsp;Nahid Nafisi,&nbsp;Roghayeh Abbasalipourkabir","doi":"10.1155/2022/1459410","DOIUrl":"https://doi.org/10.1155/2022/1459410","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is one of the leading causes of death in women worldwide. This causes an increase in free radicals, resulting in oxidative stress. The aim of this study was to determine the effect of breast cancer on oxidative stress and its relationship with hematological indices.</p><p><strong>Methods: </strong>This case-control study included 43 women with breast cancer and 37 age-matched healthy controls. Oxidative stress and its correlation with hematological profiles over seven months were evaluated. Finally, the data were compared between the two groups using the <i>t</i>-test and Pearson's test, and the results were analyzed using the SPSS 24 software.</p><p><strong>Results: </strong>The results revealed that patients with breast cancer had significantly increased hemoglobin (HB), hematocrit (HCT), mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH) levels compared with healthy subjects (<i>p</i> < 0.05). In addition, oxidative stress parameters, such as superoxide dismutase (SOD), catalase (CAT), total oxidant status (TOS), and total antioxidant capacity (TAC), were significantly elevated. Glutathione peroxidase (GPX) and malondialdehyde (MDA) were significantly lower in patients with breast cancer than in the control group (<i>p</i> < 0.05). Statistical significance in hematological indices showed a positive or negative correlation with oxidative stress parameters.</p><p><strong>Conclusion: </strong>Women with breast cancer showed a deranged complete blood count (CBC) pattern compared to healthy individuals.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33501924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands. 在荷兰早期HR+/HER2-淋巴结阴性乳腺癌患者中Oncotype DX®检测的成本和临床效益
IF 1.9 Q3 Medicine Pub Date : 2022-09-22 eCollection Date: 2022-01-01 DOI: 10.1155/2022/5909724
Felix E de Jongh, Reva Efe, Kirsten H Herrmann, Jelle A Spoorendonk

Objectives: Patients with early-stage HR+/HER2- N0 breast cancer may receive adjuvant chemotherapy in combination with surgery. However, chemotherapy does not always lead to improved survival and incurs high healthcare costs and increased adverse events. To support decision-making regarding adjuvant chemotherapy, genomic profile testing performed with tests such as the Oncotype DX® test can help healthcare practitioners decide whether chemotherapy provides any benefit to these patients. As such, a cost-consequence model was developed with the aim to estimate the economic impact of using different gene expression tests or no testing, in patients with node-negative early-stage breast cancer.

Methods: A cost-consequence model was developed to estimate the economic impact of three different scenarios in the Dutch setting: (1) Oncotype DX® test, (2) MammaPrint®, and (3) and no genomic profile testing. The model included chemotherapy costs, administration costs, short- and long-term adverse event costs, productivity loss, genomic profiling testing costs, cost of cancer recurrence, and hospitalization costs.

Results: A treatment paradigm with Oncotype DX resulted in average savings per patient of €6,768 vs. a paradigm with MammaPrint and €13,125 vs. a paradigm with no genomic testing. Furthermore, due to less patients receiving adjuvant chemotherapy through better targeting by the Oncotype DX test, fewer adverse events, sick days, practice visits, and hospitalizations were required compared to MammaPrint and no genomic profiling.

Conclusions: Testing with Oncotype DX test in Dutch clinical practice in patients with early-stage breast cancer proved to be cost-saving versus MammaPrint and no genomic profiling tests. Introducing the Oncotype DX test to the Dutch setting will likely reduce the economic resources that are required.

目的:早期HR+/HER2- N0乳腺癌患者可接受手术联合辅助化疗。然而,化疗并不总是能提高生存率,而且会导致高昂的医疗费用和增加的不良事件。为了支持辅助化疗的决策,使用诸如Oncotype DX®测试的基因组谱测试可以帮助医疗从业者确定化疗是否对这些患者有益。因此,开发了一个成本-后果模型,目的是估计在淋巴结阴性早期乳腺癌患者中使用不同基因表达检测或不进行检测的经济影响。方法:开发了一个成本-后果模型来估计荷兰环境中三种不同情况的经济影响:(1)Oncotype DX®检测,(2)MammaPrint®检测,(3)不进行基因组谱检测。该模型包括化疗费用、管理费用、短期和长期不良事件费用、生产力损失、基因组分析测试费用、癌症复发费用和住院费用。结果:与使用MammaPrint的治疗模式相比,使用Oncotype DX的治疗模式平均每位患者节省6,768欧元,与不进行基因组测试的治疗模式相比,平均每位患者节省13,125欧元。此外,由于通过Oncotype DX检测更好地靶向治疗,接受辅助化疗的患者更少,与MammaPrint相比,所需的不良事件、病假、就诊和住院次数更少,而且不需要基因组分析。结论:在荷兰早期乳腺癌患者的临床实践中,与MammaPrint相比,使用Oncotype DX检测被证明节省了成本,而且不需要进行基因组分析测试。将Oncotype DX测试引入荷兰可能会减少所需的经济资源。
{"title":"Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands.","authors":"Felix E de Jongh,&nbsp;Reva Efe,&nbsp;Kirsten H Herrmann,&nbsp;Jelle A Spoorendonk","doi":"10.1155/2022/5909724","DOIUrl":"https://doi.org/10.1155/2022/5909724","url":null,"abstract":"<p><strong>Objectives: </strong>Patients with early-stage HR+/HER2- N0 breast cancer may receive adjuvant chemotherapy in combination with surgery. However, chemotherapy does not always lead to improved survival and incurs high healthcare costs and increased adverse events. To support decision-making regarding adjuvant chemotherapy, genomic profile testing performed with tests such as the Oncotype DX® test can help healthcare practitioners decide whether chemotherapy provides any benefit to these patients. As such, a cost-consequence model was developed with the aim to estimate the economic impact of using different gene expression tests or no testing, in patients with node-negative early-stage breast cancer.</p><p><strong>Methods: </strong>A cost-consequence model was developed to estimate the economic impact of three different scenarios in the Dutch setting: (1) Oncotype DX® test, (2) MammaPrint®, and (3) and no genomic profile testing. The model included chemotherapy costs, administration costs, short- and long-term adverse event costs, productivity loss, genomic profiling testing costs, cost of cancer recurrence, and hospitalization costs.</p><p><strong>Results: </strong>A treatment paradigm with Oncotype DX resulted in average savings per patient of €6,768 vs. a paradigm with MammaPrint and €13,125 vs. a paradigm with no genomic testing. Furthermore, due to less patients receiving adjuvant chemotherapy through better targeting by the Oncotype DX test, fewer adverse events, sick days, practice visits, and hospitalizations were required compared to MammaPrint and no genomic profiling.</p><p><strong>Conclusions: </strong>Testing with Oncotype DX test in Dutch clinical practice in patients with early-stage breast cancer proved to be cost-saving versus MammaPrint and no genomic profiling tests. Introducing the Oncotype DX test to the Dutch setting will likely reduce the economic resources that are required.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33545808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Diagnostic and Prognostic Role of Serum Omentin and NGAL Levels in Egyptian Breast Cancer Patients. 血清网膜蛋白和NGAL水平在埃及乳腺癌患者中的诊断和预后作用。
IF 1.9 Q3 Medicine Pub Date : 2022-09-14 eCollection Date: 2022-01-01 DOI: 10.1155/2022/5971981
Al-Shimaa Mahmoud Abas, Mohamed H Sherif, Sara A Elmoneam Farag

Background: Breast cancer (BC) is globally the main cause of cancer-related deaths in women. Tumor biomarkers have significant role in diagnosis and predicting the prognosis and decide the specific therapy to each patient.

Aim: In this study, we investigated whether omentin and NGAL levels were altered in patients with breast cancer and the relationship between these markers and their clinicopathological parameters. Subjects and Methods. This study included 120 patients with breast cancer and 30 healthy individuals served as controls. We measured the serum level of omentin and NGAL by ELISA technique.

Results: Our results showed that there were statistically significant differences in serum omentin and NGAL levels between two groups. Also, in breast cancer patients, there was significant difference between omentin level, the same results with NGAL level and patient's age, tumor size, lymph node, and metastasis. No significant relationship was found between omentin level and tumor grade, ER, PR, and HER2. The cutoff value for the prediction of breast cancer was determined at >113.2 ng/ml for omentin and >145.3 ng/ml for NGAL with a sensitivity of 91.7% and 100%, specificity of 100% and 80%, positive predictive value of 100% and 90.9%, negative predictive value of 85.7% and 100%, and accuracy of 94.4% and 93.3%, respectively. In conclusion, serum omentin and NGAL can be used as strong diagnostic markers for breast cancer.

背景:乳腺癌(BC)是全球女性癌症相关死亡的主要原因。肿瘤生物标志物在诊断和预测预后以及决定每位患者的特异性治疗方面具有重要作用。目的:在本研究中,我们探讨乳腺癌患者网膜蛋白和NGAL水平是否发生改变,以及这些标志物与其临床病理参数的关系。研究对象和方法。这项研究包括120名乳腺癌患者和30名健康个体作为对照。采用ELISA法测定血清大网膜蛋白和NGAL水平。结果:我们的结果显示,两组患者血清网膜蛋白和NGAL水平差异有统计学意义。在乳腺癌患者中,网膜水平、NGAL水平与患者年龄、肿瘤大小、淋巴结、转移情况有显著性差异。网膜水平与肿瘤分级、ER、PR、HER2无显著相关性。预测乳腺癌的临界值,网膜entin >113.2 ng/ml, NGAL >145.3 ng/ml,敏感性分别为91.7%和100%,特异性分别为100%和80%,阳性预测值分别为100%和90.9%,阴性预测值分别为85.7%和100%,准确率分别为94.4%和93.3%。综上所述,血清大网膜蛋白和NGAL可作为乳腺癌的有力诊断指标。
{"title":"Diagnostic and Prognostic Role of Serum Omentin and NGAL Levels in Egyptian Breast Cancer Patients.","authors":"Al-Shimaa Mahmoud Abas,&nbsp;Mohamed H Sherif,&nbsp;Sara A Elmoneam Farag","doi":"10.1155/2022/5971981","DOIUrl":"https://doi.org/10.1155/2022/5971981","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) is globally the main cause of cancer-related deaths in women. Tumor biomarkers have significant role in diagnosis and predicting the prognosis and decide the specific therapy to each patient.</p><p><strong>Aim: </strong>In this study, we investigated whether omentin and NGAL levels were altered in patients with breast cancer and the relationship between these markers and their clinicopathological parameters. <i>Subjects and Methods</i>. This study included 120 patients with breast cancer and 30 healthy individuals served as controls. We measured the serum level of omentin and NGAL by ELISA technique.</p><p><strong>Results: </strong>Our results showed that there were statistically significant differences in serum omentin and NGAL levels between two groups. Also, in breast cancer patients, there was significant difference between omentin level, the same results with NGAL level and patient's age, tumor size, lymph node, and metastasis. No significant relationship was found between omentin level and tumor grade, ER, PR, and HER2. The cutoff value for the prediction of breast cancer was determined at >113.2 ng/ml for omentin and >145.3 ng/ml for NGAL with a sensitivity of 91.7% and 100%, specificity of 100% and 80%, positive predictive value of 100% and 90.9%, negative predictive value of 85.7% and 100%, and accuracy of 94.4% and 93.3%, respectively. In conclusion, serum omentin and NGAL can be used as strong diagnostic markers for breast cancer.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33486210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
The Impact of Tumor Infiltrating Lymphocytes Densities and Ki67 Index on Residual Breast Cancer Burden following Neoadjuvant Chemotherapy. 肿瘤浸润淋巴细胞密度和Ki67指数对新辅助化疗后乳腺癌残余负荷的影响。
IF 1.9 Q3 Medicine Pub Date : 2022-09-12 eCollection Date: 2022-01-01 DOI: 10.1155/2022/2597889
Aya Elmahs, Ghada Mohamed, Mostafa Salem, Dina Omar, Amany Mohamed Helal, Nahed Soliman

To avoid unnecessary neoadjuvant chemotherapy in case anticipating a poor therapy response, it is essential to find the pathological parameters that would predict pathological complete response or at least a decrease in tumor burden following neoadjuvant chemotherapy. The purpose of this study is to investigate the hypothesis that tumor infiltrating lymphocytes can predict the efficacy of neoadjuvant chemotherapy and to find the Ki67 cutoff value that best predicts the benefit of chemotherapy. 153 cases of breast cancer were chosen, based on their molecular subtype: triple negative subtype (77) and luminal, HER2-ve subtype (76). Histopathological assessment of pretherapy core biopsies was conducted to assess variable pathological parameters including TILs rates with the aid of immunohistochemical staining for CD20 and CD3. Moreover, core biopsies were stained for Ki67, and the findings were compared to the residual cancer burden following neoadjuvant chemotherapy. On analyzing and contrasting the two groups, a significant association between molecular subtype and pathological complete response was confirmed, while tumor-infiltrating lymphocytes in either group had no effect on therapy response. We used receiver operating characteristic curve analysis to determine that a cutoff of 36% for Ki67 is the most accurate value to predict complete therapy response.

为了避免在预期治疗反应较差的情况下进行不必要的新辅助化疗,有必要找到预测新辅助化疗后病理完全缓解或至少肿瘤负担减少的病理参数。本研究的目的是探讨肿瘤浸润淋巴细胞预测新辅助化疗疗效的假设,并寻找最能预测化疗获益的Ki67截止值。153例乳腺癌患者根据其分子亚型选择:三阴性亚型(77例)和luminal, HER2-ve亚型(76例)。通过CD20和CD3免疫组化染色,对治疗前核心活检进行组织病理学评估,以评估包括TILs率在内的可变病理参数。此外,对核心活检组织进行Ki67染色,并将结果与新辅助化疗后残留的癌症负担进行比较。通过对两组的分析对比,证实分子亚型与病理完全反应有显著相关性,而两组肿瘤浸润淋巴细胞对治疗反应均无影响。我们使用受试者工作特征曲线分析来确定Ki67的临界值为36%是预测完全治疗反应的最准确值。
{"title":"The Impact of Tumor Infiltrating Lymphocytes Densities and Ki67 Index on Residual Breast Cancer Burden following Neoadjuvant Chemotherapy.","authors":"Aya Elmahs,&nbsp;Ghada Mohamed,&nbsp;Mostafa Salem,&nbsp;Dina Omar,&nbsp;Amany Mohamed Helal,&nbsp;Nahed Soliman","doi":"10.1155/2022/2597889","DOIUrl":"https://doi.org/10.1155/2022/2597889","url":null,"abstract":"<p><p>To avoid unnecessary neoadjuvant chemotherapy in case anticipating a poor therapy response, it is essential to find the pathological parameters that would predict pathological complete response or at least a decrease in tumor burden following neoadjuvant chemotherapy. The purpose of this study is to investigate the hypothesis that tumor infiltrating lymphocytes can predict the efficacy of neoadjuvant chemotherapy and to find the Ki67 cutoff value that best predicts the benefit of chemotherapy. 153 cases of breast cancer were chosen, based on their molecular subtype: triple negative subtype (77) and luminal, HER2-ve subtype (76). Histopathological assessment of pretherapy core biopsies was conducted to assess variable pathological parameters including TILs rates with the aid of immunohistochemical staining for CD20 and CD3. Moreover, core biopsies were stained for Ki67, and the findings were compared to the residual cancer burden following neoadjuvant chemotherapy. On analyzing and contrasting the two groups, a significant association between molecular subtype and pathological complete response was confirmed, while tumor-infiltrating lymphocytes in either group had no effect on therapy response. We used receiver operating characteristic curve analysis to determine that a cutoff of 36% for Ki67 is the most accurate value to predict complete therapy response.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33476104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Breast Cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1